Daiichi Sankyo presents preliminary safety & efficacy data from phase 1 study of DS-3032 in AML &MDS at ASH meeting

• A total of 38 patients with relapsed/refractory AML or high-risk MDS were enrolled into the study. Five dose levels of DS-3032 (60 mg, 90 mg, 120 mg, 160 mg and 210 mg) were given. The maximum tolerated dose of DS-3032 was determined to be 160 mg once daily for 21 days in a 28 day cycle based on results from 37 patients who received at least one dose of DS-3032.
• Clinical activity of DS-3032 was observed by a reduction of bone marrow blasts at the end of the first cycle of treatment in 15 out of 26 patients who had at least one post-dose bone marrow evaluation. Complete remission was seen in two patients with relapsed/refractory AML receiving 120 mg and 160 mg of DS-3032 with a duration of approximately four months and 13 months, respectively. One patient with high-risk MDS receiving the 120 mg dose of DS-3032 achieved marrow complete remission with platelet improvement for four months. Each of the three patients experiencing a complete response showed a TP53 gene mutation while receiving treatment, which was not identified at the start of the study.
• “MDM2 inhibitors such as DS-3032 represent a promising approach in cancer therapy as they have the potential to restore the tumour suppressor protein function of p53 via release from the inhibitory effects of MDM2. Wild-type p53 plays an important role in preventing the uncontrolled growth of cancer cells,” said Courtney DiNardo, MD, MSCE, Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. “While these findings are encouraging in that single-agent clinical activity in refractory haematologic malignancies was demonstrated with DS-3032, further study with optimized dosing regimens including combination strategies is needed.”
• Five patients experienced dose limiting toxicities including two patients in the 160 mg cohort (grade 3 hypokalemia and diarrhoea) and three patients in the 210 mg cohort (grade 3 nausea/vomiting, grade 3 anorexia/fatigue and grade 2 creatinine elevation/renal insufficiency leading to early discontinuation of treatment). The most common treatment-emergent adverse events (TEAEs) of any grade (greater than 20 per cent) included nausea (73 per cent), diarrhoea (57 per cent), vomiting (33 per cent), fatigue (37 per cent), anaemia (33 per cent), thrombocytopenia (33 per cent), neutropenia (20 per cent), hypotension (30 per cent), hypokalemia (23 per cent), and hypomagnesemia (20 per cent).
• “Additional research is currently underway to further explore the appropriate dose and treatment schedule of DS-3032 as well as determine how it can be combined with other therapies,” said Antoine Yver, MD, MSc, executive vice president and global head, oncology research and development, Daiichi Sankyo. “We are committed to investigating novel approaches to treat AML and MDS in hopes of changing the standard of care for these patients.”
• The primary objectives  of the dose escalation part of the phase l study are to assess the safety, tolerability, and maximum tolerated dose or the tentative recommended phase 2 dose of DS-3032 in several haematological malignancies including refractory or relapsed acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL), chronic myleoid leukaemia (CML) in blast phase, and myelodysplastic syndrome (MDS). Secondary objectives include evaluating the pharmacokinetics and pharmacodynamic effects of DS-3032. Exploratory objectives include evaluating the efficacy of DS-3032. Further evaluation of alternative dosing schedules of DS-3032 is currently underway. 
• DS-3032 is an investigational oral selective inhibitor of the murine double minute 2 (MDM2) protein currently being investigated in three phase 1 clinical trials for solid and hematological malignancies including acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL), chronic myeloid leukaemia (CML) in blast phase, lymphoma and myelodysplastic syndrome (MDS). DS-3032 has not been approved by any regulatory authority for uses under investigation. 
• MDM2 is an ubiquitously expressed protein that plays an important role in tissue development and tightly regulates p53, a protein that functions as a tumour suppressor.1 Overexpression or oncogenic activation of MDM2 can disrupt the balanced MDM2 and p53 interaction, blocking the tumour suppressor activity and leading to solid tumors and haematological malignancies. Small molecules designed to block the MDM2-p53 interaction, reactivating p53 to suppress tumours, may be a promising therapeutic approach for the treatment of wild-type (non-mutant) p53 cancer.
• Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets.

Daiichi sankyo presents, preliminary safety, efficacy data, aml, mds, ash meeting